PepGen (PEPG) Enterprise Value (2022 - 2026)
PepGen (PEPG) posted Enterprise Value of -$132.3 million for Q1 2026, up 10.88% sequentially from -$148.5 million in Q4 2025, and down 35.31% YoY from -$204.5 million in Q1 2025.
Analysis
PepGen (PEPG) Enterprise Value (2022 - 2026) Analysis & Trends
PepGen has reported Enterprise Value for 6 years, with the latest figure at -$132.3 million in Q1 2026.
- Quarterly Enterprise Value fell 35.31% year-over-year to -$132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132.3 million (down 35.31% YoY) and the FY2025 annual result came in at -$148.5 million, down 23.52% from the prior year.
- Enterprise Value advanced to -$132.3 million in Q1 2026 per PEPG's latest filing, from -$148.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$74.7 million in Q2 2025 and troughed at -$218.8 million in Q2 2022.
- A 5-year average of -$145.9 million and a median of -$147.0 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value slumped 1682.72% in 2022, then soared 53.72% in 2025.
- Over 5 years, Enterprise Value stood at -$181.8 million in 2022, then surged by 39.25% to -$110.4 million in 2023, then retreated by 8.86% to -$120.2 million in 2024, then fell by 23.52% to -$148.5 million in 2025, then increased by 10.88% to -$132.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$132.3 million, -$148.5 million, and -$163.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.43 Mn |
| Mar 31, 2026 | -9.87 Mn |
| Dec 31, 2025 | 126.41 Mn |
| Sep 30, 2025 | -4.91 Mn |
| Jun 30, 2025 | -38.25 Mn |
| Mar 31, 2025 | -51.97 Mn |
| Dec 31, 2024 | 3.44 Mn |
| Sep 30, 2024 | 139.84 Mn |
| Jun 30, 2024 | 358.83 Mn |
| Mar 31, 2024 | 301.31 Mn |
| Dec 31, 2023 | 51.59 Mn |
| Sep 30, 2023 | -8.57 Mn |
| Jun 30, 2023 | 65.87 Mn |
| Mar 31, 2023 | 125.45 Mn |
| Dec 31, 2022 | 27.35 Mn |
| Sep 30, 2022 | 18.79 Mn |
| Jun 30, 2022 | -78.90 Mn |